Pfizer Eliquis Price Move With Cost Plus Raises Questions On Valuation

• Pfizer and Bristol Myers Squibb are partnering with Mark Cuban's Cost Plus Drug Company to offer Eliquis directly to cash-paying patients on CostPlusDrugs.com.
• The move centers on improving access and price transparency for the oral anticoagulant, one of the most widely used branded blood thinners.
• This collaboration marks a shift in how a major biopharma alliance is willing to distribute a branded drug to reach cost-sensitive patients.

For investors watching Pfizer, NYSE:PFE, this development lands as the shares trade around $27.0, with a value score of 3 and a mixed return profile. The stock shows a 7.2% gain year to date and a 26.4% return over 1 year, set against weaker 3 year and 5 year returns of 16.8% and 10.3% declines. The Eliquis partnership adds another angle to the discussion around pricing power and patient access.

This move may influence how investors think about branded drug distribution models and pricing flexibility across Pfizer's broader portfolio. It may also shape expectations around how large pharmaceutical companies respond to pressure on affordability, with potential implications for reputation, patient reach, and competitive positioning over time.

Stay updated on the most important news stories for Pfizer by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Pfizer.

📰 Beyond the headline: 4 risks and 1 thing going right for Pfizer that every investor should see.

Quick Assessment

• ✅ Price vs Analyst Target: At US$27.00, Pfizer trades about 6.7% below the US$28.93 analyst price target.
• ✅ Simply Wall St Valuation: Shares are flagged as trading 58.4% below an estimated fair value.
• ❌ Recent Momentum: The 30 day return is roughly a 1.0% decline.

There is only one way to know the right time to buy, sell or hold Pfizer. Head to Simply Wall St's company report for the latest analysis of Pfizer's Fair Value.

Key Considerations

• 📊 The Eliquis move with Cost Plus Drug Company highlights a willingness to trade margin for reach and transparency, which could be relevant for how you think about pricing risk across Pfizer's portfolio.
• 📊 Watch prescription volumes, any commentary on Eliquis economics, and how this pricing channel is discussed in future updates on revenue of US$62.6b and net income of US$7.7b.
• ⚠️ A key flagged risk is that earnings are forecast to decline on average over the next 3 years, so any pressure on Eliquis margins may matter for overall profitability and dividend coverage.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Pfizer analysis. Alternatively, you can check out the community page for Pfizer to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com